Designing a new antifungal glycoconjugate vaccine

Potential conjugate vaccines against Candida albicans, a common pathogen which in its most virulent form may cause life-threatening bloodstream infections such as bacterial meningitis in infants and immunocompromised adults, are currently being developed.

As part of the upcoming Chem Soc Rev carbohydrate chemistry themed issue, this review article by members of the Bundle Research Group from the Alberta Glycomics Centre at the University of Alberta highlights the latest and most significant prospects for candidate vaccines against C. albicans. It also contextualises their work on conjugate vaccine design and evaluation within current knowledge on antibody-carbohydrate interactions and glycoconjugate vaccines development.

Their experimental findings show that conjugate vaccines containing disaccharide or trisaccharide attached to immunogenic proteins reduced fungal burden.

graphical abstract

Related PowerPoint slides on “β1,2-Mannans Conformationally Interesting Molecules” are also available as electronic supplementary information (ESI) – take a look at these for free.

Read this Chemical Society Reviews article today:

Designing a new antifungal glycoconjugate vaccine
Margaret A. Johnson and David R. Bundle
Chem. Soc. Rev., 2013, Advance Article
DOI: 10.1039/C2CS35382B

Digg This
Reddit This
Stumble Now!
Share on Facebook
Bookmark this on Delicious
Share on LinkedIn
Bookmark this on Technorati
Post on Twitter
Google Buzz (aka. Google Reader)

Leave a Reply